Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
暂无分享,去创建一个
J. Cuzick | S. Cawthorn | A. Howell | J. Forbes | B. Bonanni | M. Dowsett | R. Mansel | I. Šestak | G. Minckwitz | C. Saunders | N. Roche | T. Palva | Jill Knox
[1] M. Cowie. National Institute for Health and Care Excellence. , 2015, European heart journal.
[2] C. Zouboulis,et al. Steroidogenesis in the skin: Implications for local immune functions , 2013, The Journal of Steroid Biochemistry and Molecular Biology.
[3] J. Cuzick,et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. LaCroix,et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data , 2013, The Lancet.
[5] C. Rapuano,et al. Dry eye syndrome in aromatase inhibitor users , 2012, Clinical & experimental ophthalmology.
[6] R. Kay. The Analysis of Survival Data , 2012 .
[7] J. Manson,et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. , 2012, The Lancet. Oncology.
[8] Jack Cuzick,et al. A breast cancer prediction model incorporating familial and personal risk factors , 2012 .
[9] S. Luoh,et al. Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease , 2011, Current eye research.
[10] Karen A Gelmon,et al. Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.
[11] K. Pritchard,et al. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer , 2011, Breast Cancer Research and Treatment.
[12] A. Jemal,et al. Global Cancer Statistics , 2011 .
[13] G. Kimmick. Faculty Opinions recommendation of Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010 .
[14] Jack Cuzick,et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.
[15] J. Cuzick,et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Thigpen. Aromatase Inhibitor–Induced Carpal Tunnel Syndrome: Results From the ATAC Trial , 2010 .
[17] J. Cuzick,et al. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Laroche,et al. Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. , 2007, The Journal of rheumatology.
[19] J. Cuzick,et al. Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.
[20] J. Forbes,et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] N. Boyd,et al. Mammographic density and the risk and detection of breast cancer. , 2007, The New England journal of medicine.
[22] V. McCormack,et al. Breast Density and Parenchymal Patterns as Markers of Breast Cancer Risk: A Meta-analysis , 2006, Cancer Epidemiology Biomarkers & Prevention.
[23] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[24] E. Campos,et al. Menopause and dry eye. A possible relationship , 2005, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[25] J. Cuzick. Aromatase inhibitors for breast cancer prevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Stephen W Duffy,et al. A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.
[27] M Baum,et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.
[28] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.
[29] D. Wickerham,et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.
[30] I. Toda,et al. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye. , 2000, Acta ophthalmologica Scandinavica.
[31] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[32] H. Johansson,et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. , 1995, Journal of the National Cancer Institute.
[33] M. Carcangiu. Re: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.
[34] C. Redmond,et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. , 1994, Journal of the National Cancer Institute.
[35] D. English,et al. Oestrogens and endometrial cancer: effect of other risk factors on the association. , 1980, Maturitas.
[36] D. Cox. Regression Models and Life-Tables , 1972 .
[37] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[38] D.,et al. Regression Models and Life-Tables , 2022 .